Hsiao D. Lieu - Nov 6, 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
EVP, Chief Medical Officer
Signature
/s/ Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Nov 6, 2023
Transactions value $
$0
Form type
4
Date filed
11/8/2023, 06:08 PM
Previous filing
Mar 6, 2023
Next filing
Jan 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award +190K 190K Nov 6, 2023 Common Stock 190K $0.84 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -190K -100% 0 Nov 6, 2023 Common Stock 190K $12.06 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Award +25K 25K Nov 6, 2023 Common Stock 25K $0.84 Direct F2, F3
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -25K -100% 0 Nov 6, 2023 Common Stock 25K $16.47 Direct F2, F3
transaction NGM Stock Option (Right to Buy) Award +100K 100K Nov 6, 2023 Common Stock 100K $0.84 Direct F2, F4
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -100K -100% 0 Nov 6, 2023 Common Stock 100K $31.93 Direct F2, F4
transaction NGM Stock Option (Right to Buy) Award +150K 150K Nov 6, 2023 Common Stock 150K $0.84 Direct F2, F5
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -150K -100% 0 Nov 6, 2023 Common Stock 150K $15.20 Direct F2, F5
transaction NGM Stock Option (Right to Buy) Award +150K 150K Nov 6, 2023 Common Stock 150K $0.84 Direct F2, F6
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -150K -100% 0 Nov 6, 2023 Common Stock 150K $5.36 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
F3 The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis.
F4 The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis.
F5 The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
F6 The shares subject to the stock option vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis.